iVeena Delivery Systems, Inc. (“iVeena”), a clinical-stage ophthalmology company developing novel pharmacologic therapies for refractive eye diseases, today announced that the first participant has been dosed in its Phase 1, first-in-human clinical study of IVMED-85 in healthy adult volunteers.

The Phase 1 study is designed to evaluate the safety and tolerability of twice daily dosing of IVMED-85. The randomized, controlled trial is enrolling healthy adult volunteers and dosing is expected to be completed in second quarter and full readout in mid-third quarter of 2026.

“Dosing the first participant in our Phase 1 study represents an important milestone in the clinical development of IVMED-85,” said Michael Burr, Chief Operating Officer. “This achievement underscores iVeena’s commitment to advancing innovative therapies that may one day transform how myopia progression is treated.”

iVeena’s lead investigational therapy IVMED-85 is being evaluated for the prevention of myopic progression. Insights from this Phase 1 trial will inform the design of future clinical studies in children with progressive myopia. A Phase 2 study is planned to begin in the second half of 2026.

About IVMED-85

Lead program IVMED-85 is a new chemical entity (NCE), preservative-free prescription eye drop to prevent myopic progression. IVMED-85 is a non-surgical, non-invasive, non-atropine daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation.

About iVeena

iVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena has licensed its lead asset to Glaukos Corporation, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first-in-class, investigational eye drop formulation for pediatric myopia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260211685415/en/